SEARCH
  Text Size A A
Improvement in activities of daily lliving (ADL) and motor performance scores at week 24
  • 25% improvement in ADL score with REQUIP XL vs 6% with placebo in a 24-week study 1†
  • 22% improvement in motor performance score with REQUIP XL vs 6% with placebo in a 24-week study 1†

   * A 6-month, randomized, double-blind, placebo-controlled study of 391 patients with Parkinson's disease who were not optimally controlled with L-dopa. Patients were randomized to either REQUIP XL + L-dopa or placebo + L-dopa. The primary end point was mean change from baseline in hours "off" at week 24.

   † Protocol-specified secondary end point; other secondary end points were measured and can be found in the EASE-PD adjunct publication.

   ‡ Mean change from baseline in UPDRS score at week 24 LOCF.

   § The ADL component of the UPDRS ranges from 0 to 52. ADL score at baseline was approximately 14.

   || The motor component of the UPDRS ranges from 0 to 108. Motor score at baseline was approximately 30.



Significant reduction in daily

Reduction in daily L-dopa dose vs. placebo at week 24
  • 34% reduction in L-dopa dose in patients treated with REQUIP XL compared to 21% with placebo 1†† ‡‡
  • 93% of patients treated with REQUIP XL maintained reduction in daily
    L-dopa dose vs 72% receiving placebo (P<0.001) 1†† ‡‡

   A 6-month, randomized, double-blind, placebo-controlled study of 391 patients with Parkinson’s disease who were not optimally controlled with L-dopa. Patients were randomized to either REQUIP XL + L-dopa or placebo + L-dopa. The primary end point was mean change from baseline in hours “off” at week 24.

  # Statistical significance was achieved at each assessment point except week 1.

  ** Adjusted mean treatment difference between REQUIP XL and placebo of -1.7 hours.

 †† A 6-month, randomized, double-blind, placebo-controlled study of 391 patients with Parkinson's disease who were not optimally controlled with L-dopa. As adjunctive therapy to L-dopa, patients were randomized to either REQUIP XL + L-dopa or placebo + L-dopa. The primary end point was mean change from baseline in hours "off" at week 24.

 ‡‡ Protocol-specified secondary end point at week 24; other secondary end points were measured and can be found in the EASE-PD adjunct publication.

NEXT:
Safety of REQUIP XL

Important Safety Information

REQUIP XL has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur more frequently during initial treatment or with an increase in dose. Increase in blood pressure and changes in heart rate may occur. Hallucinations may occur at any time during treatment. Impulse control symptoms, including pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole. REQUIP XL may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing dyskinesia.

Complete Prescribing Information for REQUIP XL